SecBot SecBot
8-K ·Filed May 19, 2026

ARTV

Artiva Biotherapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001193125-26-229714
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine executive reorganization with no financial shock. Monitor for the CFO search outcome and any associated disclosure; the CEO doubling as CFO is a temporary structure that may signal cost discipline or delayed hiring. The R&D-focused appointment of Miralles (who was already consulting on clinical/regulatory strategy) is a positive for pipeline execution but not a catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.55
T+0 close · May 19, 2026 · via day close
Latest settled
+32.16%
T+60 · $11.30
Vs SPY
+25.87%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 19 $8.55entry
  2. T+1 · 6mo ago −8.30%α −9.34% · $7.84
  3. T+5 · 6mo ago −8.19%α −10.43% · $7.85
  4. T+20 · 5mo ago +16.26%α +15.27% · $9.94
  5. T+60 · 3mo ago +32.16%α +25.87% · $11.30
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Artiva Biotherapeutics announced a reorganization of its executive team: CFO Thad Huston is departing effective May 22, 2026 with a $135,000 severance; CEO Fred Aslan assumes the principal financial officer role; and Diego Miralles transitions from the Board to President and Head of R&D with a $600,000 salary and inducement equity grants of 232,500 options and 77,500 RSUs. The CFO departure without a named successor creates a temporary gap in financial leadership, though the CEO taking over the role suggests internal continuity.

Key Facts

  • CFO Thad Huston agreed to separation effective May 22, 2026; no replacement named yet; receives ~$135,000 severance (3 months salary) plus COBRA.
  • CEO Fred Aslan appointed as principal financial and accounting officer, adding to his CEO and board member roles.
  • Diego Miralles resigned from the Board effective May 18, 2026 to become President and Head of R&D; receives $600,000 base salary, 45% target bonus, and inducement awards of 232,500 options + 77,500 RSUs.
  • Board size reduced from 8 to 7 members following Miralles' departure.
  • All separations stated as not resulting from any dispute or disagreement with the company.

Financial Impact

CFO severance of approximately $135,000 is immaterial relative to the company's $228M market cap; inducement equity grants represent potential dilution of roughly 0.3% of outstanding shares.

dilution

Risk Factors

  • Lack of a permanent CFO may strain financial reporting bandwidth if the CEO is overextended.
  • Inducement equity grants add modest dilution over the vesting period.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-229714
Document: 0001193125-26-229714-index-headers.html0001193125-26-229714
Document: 0001193125-26-229714-index.html0001193125-26-229714
Document: 0001193125-26-229714.txt0001193125-26-229714

Track record

33 reports on ARTV

Performance horizon

11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
  2. Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
  3. Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
  4. Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
  5. Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
  6. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  7. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  10. Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
Showing 10 of 33

US Market Status

Market Closed · Opens in 7h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 19, 2026